Director FP&A, R&D and G&A
Apply NowCompany: Avadel Management Corporation
Location: Chesterfield, MO 63017
Description:
About Avadel Pharmaceuticals plc
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, other approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. LUMRYZ TM (sodium oxybate) extended release for oral suspension, applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted night's sleep. An extended-release medication sounds like a simple innovation, but it has been lacking for more than 20 years, and we believe this can be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA also found LUMRYZ to be clinically superior to currently marketed twice-nightly oxybate products and granted LUMRYZ seven years of Orphan Drug Exclusivity. In particular, FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal awakening to take a second dose.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage - our "secret sauce." The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We need individuals who will dive in, roll up their sleeves, and join us to continue the LUMRYZ launch and our mission to serve the narcolepsy community.
Position Summary:
The Director of FP&A, R&D and G&A will be a critical member of the finance team and is responsible for collaborating with the G&A and R&D organizations to provide strategic, and operational insights to help shape the direction of the company and accelerate its growth. As a consultative partner to cross-functional leaders, this role encourages data-driven decision making, process improvement, and supports business growth. Activities include, but are not limited to, financial management and insights into:
This includes, but is not limited to, leading the annual budget and recurring forecast of the Company's expense base for the R&D and G&A functions - using a zero-based approach, the financial review of purchase orders, and the dissemination of spend reports to internal business partners.
Essential Functions:
Experience and Qualifications:
Competencies and Behaviors:
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.
Who We Are: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Oxybate therapy is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients living with narcolepsy. However, other approved oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night. LUMRYZ TM (sodium oxybate) extended release for oral suspension, applies our proprietary drug delivery technology to allow for a single bedtime dose, eliminating the need to have a forced awakening during the middle of the night and giving patients the chance for an uninterrupted night's sleep. An extended-release medication sounds like a simple innovation, but it has been lacking for more than 20 years, and we believe this can be transformative for people with narcolepsy. For more information, please visit www.avadel.com or check out narcolespydisrupts.com.
What We Do: LUMRYZ was approved by the U.S. Food and Drug Administration (FDA) on May 1, 2023, to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA also found LUMRYZ to be clinically superior to currently marketed twice-nightly oxybate products and granted LUMRYZ seven years of Orphan Drug Exclusivity. In particular, FDA found that LUMRYZ makes a major contribution to patient care over currently available, twice-nightly oxybate products by providing a once-nightly dosing regimen that avoids nocturnal awakening to take a second dose.
How We Work: At Avadel, patients are the reason we exist, and our employees are our greatest competitive advantage - our "secret sauce." The way we work is as important as the results we achieve. Our employees work together as ONE team and live our Values, which is what makes working at Avadel so special and why we will win for patients. Our ONE Team approach fosters a culture based on being relentless for patients, having confidence with humility, being courageous, taking insights to impact, and togetherness. In everything we do, we live the Avadel Values so we can be our best for our patients, our community and each other.
We need individuals who will dive in, roll up their sleeves, and join us to continue the LUMRYZ launch and our mission to serve the narcolepsy community.
Position Summary:
The Director of FP&A, R&D and G&A will be a critical member of the finance team and is responsible for collaborating with the G&A and R&D organizations to provide strategic, and operational insights to help shape the direction of the company and accelerate its growth. As a consultative partner to cross-functional leaders, this role encourages data-driven decision making, process improvement, and supports business growth. Activities include, but are not limited to, financial management and insights into:
- clinical trial programs,
- employee benefit programs,
- legal spend, and
- special projects that may include new business initiatives and other ad-hoc projects.
This includes, but is not limited to, leading the annual budget and recurring forecast of the Company's expense base for the R&D and G&A functions - using a zero-based approach, the financial review of purchase orders, and the dissemination of spend reports to internal business partners.
Essential Functions:
- Lead and coordinate the preparation of the annual budget and recurring business forecast for the Company's R&D and G&A functions, using a zero-based approach.
- Provide financial management and oversight of clinical trial programs and related contracts, specifically with CROs. Coordinate and perform analyses to ensure that key financial accruals are captured within the forecast and actual results of the company in a timely and accurate manner.
- Analyze business performance, identify trends, and recommend actionable strategies for improving financial outcomes. Advise on key business planning assumptions, trade-offs, and scenarios to support strategic decisions within the business.
- Support the strategic evaluation of potential employee benefit programs or other similar analyses by providing financial modeling and analysis.
- Produce and disseminate operating expense reports to functional leads on an ongoing basis. Analyze results, prepare variance explanations, and assess impacts to the annual budget and/or recurring forecast. This includes, but is not limited to, monthly operating expense summaries, detailed travel & entertainment summaries, and vendor commitment summaries.
- Partner with accounting team and functional leads to develop / assess operating expense accruals.
- Ensure purchase order requests align with departmental budgets and coordinate with accounting to ensure cost centers / general ledger coding is accurate.
- Provide financial modeling and analysis support to annual planning process and quarterly forecasts, including cash planning.
Experience and Qualifications:
- Bachelor's degree, preferably in Business, Accounting or Finance.
- MBA and/or CPA is preferred.
- 7+ years of relevant experience, preferably in the pharmaceutical or similar industry.
Competencies and Behaviors:
- Must possess strong analytical and problem-solving skills, business acumen, leadership skills, exceptional interpersonal and communication skills - proven ability to interface effectively and influence senior levels of the organization.
- Proven success building relationships with internal stakeholders.
- Recognizes problems and responds, systematically gathers information, sorts through complex issues, seeks input from others, addresses root cause of issues, makes timely decisions, can make difficult decisions, uses consensus when possible, and communicates decisions to others.
- Excellent communication and interpersonal skills with the ability to interface comfortably at all levels both internally and externally.
- Ability to analyze, solve problems, and adapt to changing organizational and operational needs.
- Ability to work collaboratively with all functions.
- Ability to handle confidential information.
Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. Avadel is committed to equal employment opportunities and non-discrimination in employment. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. Avadel does not discriminate in employment on the basis of race, color, religion, sex, sexual orientation, national origin, age, disability, genetic information, marital status, ancestry, gender, gender identity, pregnancy, status as a covered veteran, or any other characteristic protected by federal, state, and/or local law. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.